A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study to Assess Efficacy and Safety of One Dose Level of Oral AZD0284 Given for Four Weeks, Compared to Placebo, in Patients With Moderate to Severe Plaque Psoriasis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study to Assess Efficacy and Safety of One Dose Level of Oral AZD0284 Given for Four Weeks, Compared to Placebo, in Patients With Moderate to Severe Plaque Psoriasis

Suspended
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs AZD 0284 (Primary)
  • Indications Plaque psoriasis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms DERMIS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Apr 2018 Status changed from recruiting to suspended due to preclinical findings that are currently under evaluation
    • 20 Dec 2017 Planned End Date changed from 7 Sep 2018 to 8 Aug 2018.
    • 20 Dec 2017 Planned primary completion date changed from 7 Sep 2018 to 8 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top